Payment overview · 2025
General Payments
$279.41
10 reported records · 4 companies
Healthcare provider profile · identity verified
Natalie Renea Keyes, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · COLLINS, MS · NPI 1285144584
Verified facts
What the public records show
CMS Open Payments records show Natalie Renea Keyes, FNP received $279.41 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $164.64 | 58.9% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $79.40 | 28.4% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $20.18 | 7.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.19 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.41 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $164.64 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $79.40 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 58 |
| Losartan Potassium | Losartan Potassium | 216 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 32 |
| Potassium Chloride | Potassium Chloride | 208 | 28 |
| Synthroid | Levothyroxine Sodium | 205 | 21 |
| Famotidine | Famotidine | 202 | 27 |
| Omeprazole | Omeprazole | 193 | 31 |
| Metformin Hcl | Metformin Hcl | 183 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 33 |
| Montelukast Sodium | Montelukast Sodium | 130 | 19 |
| Risperidone | Risperidone | 124 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 18 |
| Gabapentin | Gabapentin | 122 | 19 |
| Lisinopril | Lisinopril | 115 | 16 |
| Furosemide | Furosemide | 112 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 95 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 17 |
| Meloxicam | Meloxicam | 83 | 18 |
| Lacosamide | Lacosamide | 82 | suppressed |
| Jardiance | Empagliflozin | 80 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 16 |
| Lamotrigine | Lamotrigine | 73 | suppressed |
| Enulose | Lactulose | 72 | suppressed |
| Levetiracetam | Levetiracetam | 72 | suppressed |
| Topiramate | Topiramate | 69 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 67 | 11 |
| Lorazepam | Lorazepam | 65 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 64 | 11 |
| Linzess | Linaclotide | 63 | 11 |
| Olanzapine | Olanzapine | 63 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 61 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 61 | suppressed |
| Sucralfate | Sucralfate | 60 | 11 |
| Clonidine Hcl | Clonidine Hcl | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 15 |
| Simvastatin | Simvastatin | 57 | 11 |
| Megestrol Acetate | Megestrol Acetate | 56 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Carbamazepine Er | Carbamazepine | 49 | suppressed |
| Carvedilol | Carvedilol | 49 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 44 | 14 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 40 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Phenobarbital | Phenobarbital | 32 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Prednisone | Prednisone | 29 | 24 |
| Eliquis | Apixaban | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Valproic Acid | Valproic Acid | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Briviact | Brivaracetam | 23 | suppressed |
| Diazepam | Diazepam | 23 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Nayzilam | Midazolam | 20 | suppressed |
| Perphenazine | Perphenazine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Desmopressin Acetate | Desmopressin Acetate | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.41 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Fintepla, LYBALVI, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with UCB, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error